Patrick Campbell

An analysis of Veterans Affairs data from more than 20,000 people with diabetes provides an overview of the associations of CGM initiation with improved glycemic control and reduced hospitalization in this patient population.

An analysis of data from more than 5000 youths with T1D offers insight into the comparative ability of different treatment modalities for achieving glycemic control and optimal time in range.

Using data from nearly 2 million US patients with a documented COVID-19 infection, a new study provides an overview of the impact of vaccination, both full and partial, on risk of MACE following infection.

A genome-wide genetic association study using mendelian randomization provides insight into the causal relationships between HDPs and coronary artery disease and ischemic stroke later in life.

A systematic review and meta-analysis of data from more than a dozen RCTs provide a comprehensive overview of the effects of metformin plus oral contraceptives compared to oral contraceptives alone in women with polycystic ovary syndrome without obesity.

Data from the phase 2 CLUE trial provide insight into the safety and efficacy of tigulixostat as a serum urate-lowering therapy in patients with gout with hyperuricemia.

Using data from a pair of major studies, investigators from the Harvard T.H. Chan School of Public Health shed new light on the impact of low-carbohydrate diet scores in people with type 2 diabetes.

An analysis of data from more than 20,000 adults with a documented COVID-19 infection from Los Angeles, CA has brought forth results the investigators suggest prove the association between COVID-19 infection and increased risk of type 2 diabetes, regardless of vaccination status.

An analysis of actigraphy data obtained from the MESA Sleep Ancillary Study indicates irregularities in sleep patterns, particularly in duration and timing of sleep, were linked to increased markers of subclinical atherosclerosis, including increased coronary artery calcium burden.

Results of the CaReMe HF Study, which pooled registry data from 11 countries spanning 2018-2021, suggest the prevalence of heart failure could be as high as 2% of the general population and also offers insight into trends in uptake of GDMT among these patients.

An analysis of NHIS data from 2016-2021 indicates the rate of overweight or obesity among adults with type 1 diabetes was comparable to the rate among the general population, but these people were less likely to receive lifestyle recommendations from their providers.

New data from a predefined secondary analysis of the STROKE-AF trial provides insight into the 3-year incidence of atrial fibrillation among patients with a history of ischemic stroke caused by atherosclerosis.

An analysis of the HAPO Follow-up Study is shedding light on associations between birth weight categories and risk of diabetes 10-14 years after delivery in mothers.

A retrospective cohort study of more than 1200 patients who underwent bariatric surgery suggests a fully remote preoperative evaluation performed via telemedicine was noninferior to in-person evaluations for clinical outcomes and health care utilization.

An analysis of survey data from more than 2000 patients in Western Sweden is providing insight into how the impact of inflammatory joint disease on health-related quality of life differs among those with gout, RA, PsA, and ankylosing spondylitis.

A phase 2 trial published in NEJM describes the effects of the oral selective kappa opioid receptor agonist difelikefalin in patients with notalgia paresthetica—a condition with no FDA-approved therapies.

Announced on February 7, the US FDA notification is aimed at alerting consumers around presence of sildenafil and tadalafil in PrimeZen Black 6000, which the agency purports could pose a significant risk for people using nitrates for other chronic conditions, such as diabetes and cardiovascular disease.

Further adding to the discussion surrounding the impact of endocrine-disrupting chemicals, an analysis of data from the SWAN Multipollutant Study suggests increased exposure to phthlates was linked to a 30-63% increase in risk of developing diabetes among White women in midlife.

Leveraging data from the Tromsø study, the D2d study, and the DPVD study, a systematic review and meta-analysis concluded vitamin D supplementation could help reduce risk of progression to diabetes by 15% among people with prediabetes.

A new-user comparator study of adults with type 2 diabetes indicates use of SGLT2 inhibitors was associated with a 54% lower risk of hospitalizations for heart failure and a 15% lower risk of a modified MACE outcome compared to use of DPP-4 inhibitors.

An analysis of more than a dozen cohort studies containing data from more than 30,000 offspring provides clinicians with the most detailed overview yet of differences in cardiometabolic health outcomes in those conceived naturally compared to those conceived with use of assisted reproductive technologies.

An analysis of data from the Rochester Epidemiology Project suggests those with breast cancer or lymphoma who received treatment with anthracycline therapy experienced a more than doubling in risk of heart failure compared to controls without cancer.

In recognition of Go Red for Women Day on February 3, this feature shines a spotlight on the hurdles faced by women in cardiology and offers perspective on the battle for gender-based equity in medicine from the perspective of a pair of female leaders.

An analysis of data from the China Kadoorie Biobank study suggests cumulative exposure to estrogen was associated with stroke risk in postmenopausal women.

On February 2, Abbott announced their FlexAbility™ Ablation Catheter, Sensor Enabled had received an expanded approval from the US Food and Drug Administration and their TactiFlex™ Ablation Catheter, Sensor Enabled received a CE Mark.

A study presented at the International Stroke Conference 2023 suggests the plasma metabolite gluconic acid could serve as a race-specific biomarker for identifying increased risk of hypertension and stroke in Black adults.

Announced on February 1, the US Food and Drug Administration's approval of daprodustat (Jesduvroq) represents their first approval of an oral agent for the treatment of anemia caused by chronic kidney disease in people on dialysis.

Research from investigators in Ontario, Canada suggests the plateau in rates of cardiovascular disease and hospitalizations among people with type 2 diabetes seen in the last decade is masking a growing income-based disparity.

Using data from more than 2 million US adults with nonsurgical hospitalizations, a new study from the Mayo Clinic is sounding the alarm on the increased cardiovascular risk associated with developing sepsis.